|
|||||
|
|
SARS-CoV-2 (COVID-19) serology: implications for clinical practice,laboratory medicine and public health |
|
| Authors: | Paul Van Caeseele for the Canadian Public Health Laboratory Network Dana Bailey for the Canadian Society of Clinical Chemists Sarah E. Forgie for the Association of Medical Microbiology Infectious Disease Canada Tanis C. Dingle for the Canadian Association for Clinical Microbiology Infectious Diseases Mel Krajden for the COVID- Immunity Task Force |
| Affiliation: | Cadham Provincial Public Health Laboratory (Van Caeseele), Winnipeg, Man.; Dynacare (Bailey), Brampton, Ont.; Division of Pediatric Infectious Diseases (Forgie), Department of Pediatrics, University of Alberta, Edmonton, Alta.; Alberta Precision Laboratories (Dingle), Edmonton, Alta.; and Department of Pathology and Laboratory Medicine (Krajden), University of British Columbia, Vancouver, BC. |
| Abstract: | |
| Keywords: | |